TY - JOUR
T1 - Treatment considerations of cervical spondylotic myelopathy
AU - Shiban, Ehab
AU - Meyer, Bernhard
N1 - Publisher Copyright:
© 2014 American Academy of Neurology.
PY - 2014
Y1 - 2014
N2 - Cervical spondylotic myelopathy (CSM) is the leading cause of myelopathy in patients over age 50 years. Despite advances, CSM remains a clinical diagnosis and its natural history remains unclear. The treatment of CSM is controversial, especially in patients with mild or moderate clinical disease without rapid progression of symptoms. Herein, we begin with a clinical vignette followed by a brief description of the clinical problems. We discuss evaluation, treatment, and recommendations for the treatment of CSM. Emphasis is drawn to areas of uncertainty and present level of evidence for the treatment modalities of CSM.
AB - Cervical spondylotic myelopathy (CSM) is the leading cause of myelopathy in patients over age 50 years. Despite advances, CSM remains a clinical diagnosis and its natural history remains unclear. The treatment of CSM is controversial, especially in patients with mild or moderate clinical disease without rapid progression of symptoms. Herein, we begin with a clinical vignette followed by a brief description of the clinical problems. We discuss evaluation, treatment, and recommendations for the treatment of CSM. Emphasis is drawn to areas of uncertainty and present level of evidence for the treatment modalities of CSM.
UR - http://www.scopus.com/inward/record.url?scp=84925859564&partnerID=8YFLogxK
U2 - 10.1212/CPJ.0000000000000050
DO - 10.1212/CPJ.0000000000000050
M3 - Article
AN - SCOPUS:84925859564
SN - 2163-0402
VL - 4
SP - 296
EP - 303
JO - Neurology: Clinical Practice
JF - Neurology: Clinical Practice
IS - 4
ER -